Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.

In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., ...

The widespread use of antibiotics in industrial animal agriculture is contributing to the rise of antibiotic resistance, with ...

Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...

HHS Secretary Robert F. Kennedy Jr. plans to axe members of the department’s vaccine-centric panels of outside advisers who he deems to be too cozy with the drug industry.

The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive changes.

Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration has determined the shortage of Wegovy and Ozempic is resolved. “The ...

Shares of Novo Nordisk (NVO) are up 6% in pre-market trading after a FDA drug shortage notice indicated that a shortage of several versions of ...

Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...